Hybrid membrane-camouflaged hollow prussian blue nanoparticles for shikonin loading and combined chemo/photothermal therapy of metastatic TNBC

Liang, Jiahao; Wang, Chao; Fan, Jialong; Xie, Qingji; Yu, Zhenlong; Liu, Bin; Tian, Ye; Ning, Jing; Feng, Lei; Wang, Wei; Ma, Xiaochi

doi:10.1016/j.mtadv.2022.100245

Cited by 12 publications

(9 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…International Journal of Nanomedicine 2023:18 1206 PEI@HPB@SHK to prepare HMGPHS NPs. 130 Decreased phagocytosis of macrophages in vitro and extended drug halflife in vivo suggested membrane coating has promoted immune evasion and prolonged the circulation time of HMGPHS NPs. Excellent homotypic targeting ability and anticancer activity in vitro and vivo may owe to the homing effect of 4T1 membrane and synergetic effect of photothermal therapy (PTT) and chemotherapy, respectively.…”

Section: Dovepressmentioning

confidence: 99%

Promising Nanomedicines of Shikonin for Cancer Therapy

Yan¹,

Li²,

Sun³

et al. 2023

IJN

View full text Add to dashboard Cite

Malignant tumor, the leading cause of death worldwide, poses a serious threat to human health. For decades, natural product has been proven to be an essential source for novel anticancer drug discovery. Shikonin (SHK), a natural molecule separated from the root of Lithospermum erythrorhizon, shows great potential in anticancer therapy. However, its further clinical application is significantly restricted by poor bioavailability, adverse effects, and non-selective toxicity. With the development of nanotechnology, nano drug delivery systems have emerged as promising strategies to improve bioavailability and enhance the therapeutic efficacy of drugs. To overcome the shortcoming of SHK, various nano drug delivery systems such as liposomes, polymeric micelles, nanoparticles, nanogels, and nanoemulsions, were developed to achieve efficient delivery for enhanced antitumor effects. Herein, this review summarizes the anticancer pharmacological activities and pharmacokinetics of SHK. Additionally, the latest progress of SHK nanomedicines in cancer therapy is outlined, focusing on long circulation, tumor targeting ability, tumor microenvironment responsive drug release, and nanosystem-mediated combination therapy. Finally, the challenges and prospects of SHK nanomedicines in the future clinical application are spotlighted.

show abstract

Section: Dovepressmentioning

confidence: 99%

Promising Nanomedicines of Shikonin for Cancer Therapy

Yan¹,

Li²,

Sun³

et al. 2023

IJN

View full text Add to dashboard Cite

show abstract

“…Liang et al obtained a biomimetic nanoplatform for combination therapy by hollow PB NPs (HPB) loading drug Shikonin (SHK) and ICG, and wrapping mixed membranes of erythrocytes and 4T1 cancer cells. 129 The hybrid membrane camouflage strategy endowed the nanoplatform with longer blood circulation and good targeting ability, allowing the drug to accumulate more effectively at the tumour. ICG and PB could improve the photothermal performance of the biomimetic nanoplatform, improving the efficacy of photothermal therapy.…”

Section: Pttmentioning

confidence: 99%

Section: Combinedmentioning

confidence: 99%

Recent advances in Prussian blue-based photothermal therapy in cancer treatment

Tang

et al. 2023

Biomater. Sci.

View full text Add to dashboard Cite

show abstract

“…PBNP was synthesized according to the previous method [33]. 7.5 g PVP and 330mg K 3 [Fe(CN) 6 ]•3H 2 O were weighted and dissolved in 0.1 M 100 mL HCl, and stirred at 800 rpm for 1 h, and then conduct oil bath at 80 °C for 20 h. PBNPs were collected after centrifugation, washing, and freeze-drying.…”

Section: Synthesis Of Prussian Blue Nanoparticles (Pbnps)mentioning

confidence: 99%

Bufotalin-loaded biomimetic prussian blue nanoparticles for colorectal cancer chemo-photothermal therapy via induce ferroptosis

Tian

Luo

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Background: As a ferroptosis-inducing platform, based on its release of iron and ferrous ions to induce production of reactive oxygen species (ROS), it has attracted extensive attention in cancer treatment. Since iron-based nanomaterials such as prussian blue (PB), can only produce limited ROS. Bufotalin (CS-5), a promising ferroptosis inducer, was introduced to improve the efficiency of ferroptosis. However, the clinical application of CS-5 was limited by cardiotoxicity and high renal clearance rate. Therefore, we constructed a biomimetic nanosystem (PB@CS-5@M) with satisfactory tumor enrichment ability and long blood circulation time for the treatment of colorectal cancer induced by ferroptosis. Results: In this work, the PB@CS-5@M has efficient loading of CS-5, which significantly reduces the cardiotoxicity of CS-5. After photothermal therapy, the high temperature caused by laser stimulation triggers the release of CS-5, iron and ferrous ions to kill colorectal cancer cells. Furthermore, the ability of CS-5 to significantly down-regulate the expression of GPX4 and HIF-1a, induce ROS production and damage mitochondria to induce ferroptosis in colorectal cancer was amplified. In addition, the down-regulation of HSP70 expression under laser stimulation effectively improved the chemosensitivity of HCT116 cells to CS-5. Conclusions: The chemotherapeutic effect of CS-5 combined with the photothermal effect of PB can effectively treat colon cancer by inducing ferroptosis.

show abstract

Hybrid membrane-camouflaged hollow prussian blue nanoparticles for shikonin loading and combined chemo/photothermal therapy of metastatic TNBC

Cited by 12 publications

References 46 publications

Promising Nanomedicines of Shikonin for Cancer Therapy

Promising Nanomedicines of Shikonin for Cancer Therapy

Recent advances in Prussian blue-based photothermal therapy in cancer treatment

Bufotalin-loaded biomimetic prussian blue nanoparticles for colorectal cancer chemo-photothermal therapy via induce ferroptosis

Contact Info

Product

Resources

About